Facebook Instagram Twitter Linkedin Youtube Podcast

Duchenne News Tags: Santhera

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FDA FibroGen Italfarmaco NS Pharma PepGen Pliant Therapeutics PTC Therapeutics REGENXBIO Santhera Sarepta Therapeutics Solid Biosciences Wave Life Sciences
June 20, 2023

Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties

Santhera announces that it has signed an exclusive license and collaboration agreement for vamorolone in North America with Catalyst Pharmaceuticals.
Read More
April 25, 2023

Santhera Announces Completion of Mid-Cycle Review Meeting by FDA of Vamorolone for Duchenne

Santhera announces completion of vamorolone NDA mid-cycle review meeting by FDA
Read More
January 9, 2023

Santhera and ReveraGen Announce FDA Acceptance of New Drug  Application for Vamorolone in Duchenne Muscular Dystrophy 

Santhera and ReveraGen Announce FDA Acceptance of New Drug  Application for Vamorolone in Duchenne Muscular Dystrophy
Read More
October 28, 2022

Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone
in Duchenne Muscular Dystrophy

Santhera and ReveraGen submit NDA to FBA for vamorolone in treatment of Duchenne
Read More
October 6, 2022

Santhera Provides Update on Submission of Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy

Santhera Provides Updates on Submission of Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy
Read More
June 30, 2022

Santhera Updates on Ongoing NDA Submission for Vamorolone

On June 29, 2022, Santhera announced that the clinical module of its rolling new drug application (NDA) for vamorolone in Duchenne muscular dystrophy has been submitted to the U.S. Food...
Read More

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Gold Transparency 2022 Candid. Logo
Sitemap
© 2024 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*) 





    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Register Now

    Experience the magic this summer!

    Apply Today

    How is the rare disease community accomplishing goals?

    Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

    Register Today

    Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

    Give Today

    Accessible Vehicle Fund Applications Open

    Apply Today